The arsenal of post-NAC methods has been replenished in recent years with new highly effective drugs (TD-M1 for HER2-positive BC; CDK4/6 inhibitors for hormone-dependent, HER2-negative BC; capecitabine and immunotherapy for triple-negative BC; olaparib for BRCA-associated BC). Here, ERBB2 is linked to breast cancer.